The Latest Analyst Ratings for Stoke Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish ratings for Stoke Therapeutics (NASDAQ:STOK) within the last quarter, with 5 bullish, 2 somewhat bullish, and no indifferent or bearish ratings. The average 12-month price target for Stoke Therapeutics has increased by 45.0% from the previous average price target of $20.00 to $29.0.
July 31, 2023 | 8:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stoke Therapeutics has received positive ratings from analysts, with an increased 12-month price target. This could potentially lead to an increase in the stock's price.
Analysts' ratings are a significant factor that investors consider when making investment decisions. The bullish ratings and increased price target for Stoke Therapeutics indicate a positive outlook for the stock, which could lead to an increase in its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100